盐酸吉西他滨联合立体定向放疗治疗局部晚期胰腺癌的效果评价

季洪兵; 陈忠华

doi:10.3969/j.issn.1001-5256.2016.03.030

盐酸吉西他滨联合立体定向放疗治疗局部晚期胰腺癌的效果评价

DOI: 10.3969/j.issn.1001-5256.2016.03.030

1. 福州市第一医院放疗科
2. 南京军区福州总医院放疗科

详细信息

中图分类号: R735.9
计量
- 文章访问数: 1966
- HTML全文浏览量: 12
- PDF下载量: 364
- 被引次数: 0
出版历程
- 收稿日期: 2015-08-27
- 出版日期: 2016-03-20

Therapeutic effect of gemcitabine hydrochloride combined with stereotactic radiotherapy for locally advanced pancre-atic cancer

Department of Radiation Oncology, Fuzhou Municipal First Hospital

摘要

摘要: 目的评价盐酸吉西他滨联合立体定向放疗治疗局部晚期胰腺癌的临床疗效。方法收集2008年6月-2013年6月福州总医院收治的初治无法手术切除的局部晚期胰腺癌患者122例,按治疗方法分为盐酸吉西他滨联合立体定向放疗治疗（A组,n=56）和吉西他滨单药治疗（B组,n=66）。记录治疗后患者病情变化情况、毒副反应及死亡时间。计数资料组间比较采用χ2检验,采用Kaplan-Meier法绘制生存曲线。结果 A组治疗后有效率67.8%（38/56）,B组治疗后有效率22.7%（15/66）,2组比较差异有统计学意义（χ2=25.11,P<0.01）;A组止痛有效率95.8%,B组止痛有效率77.2%,2组比较差异有统计学意义（χ2=7.39,P<0.01）;A组1年生存率58.9%（33/56）,2年生存率28.6%（16/96）,中位生存时间12.8个月,B组1年生存率31.8%（21/66）,2年生存率10.6%（7/66）,中位生存时间7.9个月,两组比较差异均有统计学意义（χ2分别为9.03、6.39、15.51,P值均<0.01）。结论盐酸吉西他滨联合立体定向放疗具有较好的...
- 胰腺肿瘤 /
- 放射外科手术 /
- 药物疗法 /
- 治疗结果
Abstract: Objective To investigate the clinical therapeutic effect of gemcitabine hydrochloride combined with stereotactic radiotherapy for locally advanced pancreatic cancer. Methods A total of 122 previously untreated patients with locally advanced pancreatic cancer who were not able to undergo surgical resection and were admitted to Fuzhou General Hospital from June 2008 to June 2013 were selected,and according to the therapies,they were divided into the group with a combination of gemcitabine hydrochloride and stereotactic radiotherapy( group A,n = 56) and the group with gemcitabine therapy alone( group B,n = 66). The changes in condition,toxic and side effects,and death time were recorded. The chi- square test was applied for comparison between groups,and the Kaplan- Meier method was applied for plotting survival curves. Results There was a significant difference in response rate between group A and group B [67. 8%( 38 /56) vs22. 7%( 15 /66),χ2= 25. 11,P < 0. 01]; the effective pain- relieving rate showed a significant difference between group A and group B( 95. 8% vs 77. 2%,χ2= 7. 39,P < 0. 01); there were significant differences in 1- year survival rate,2- year survival rate,and median survival time between the two groups [58. 9%( 33 /56) vs 31. 8%( 21 /66),χ2= 9. 03,P < 0. 01; 28. 6%( 16 /56) vs 10. 6%( 7 /66),χ2= 6. 39,P < 0. 01; 12. 8 months vs 7. 9 months; χ2= 15. 51,P < 0. 01]. Conclusion Gemcitabine hydrochloride combined with stereotactic radiotherapy has good short- and long- term efficacy,and toxic and side effects are tolerable.
- pancreatic neoplasms /
- radiosurgery /
- drug therapy /
- treatment outcome

HTML全文

参考文献(14)

[1]PARKER SL,TONG T,BOLDEN S,et al.Cancer Statistics[J].CA Cancer J Clin,1996,46(1):5-27.

[2]ZHI YH,QI GZ.Early diagnosis and treatment of 127 cases of pancreatic head carcinoma[J].Cancer Res Clin,2012,32(12):842-843.(in Chinese)智永宏,奇广珍.胰头癌早期诊断和治疗127例[J].肿瘤研究与临床,2012,32(12):842-843.

[3]KIM R,SAIF MW.Is there an optimal neoadjuvant therapy for locally advanced pancreatic cancer[J].JOP,2007,8(3):279-288.

[4] HUGUET F,GIRARD N,GUERCHE CS,et al.Chemoradiotherapy in the management of locally advanced pancreatic carcinoma:a qualitative systematic review[J].J Clin Oncol,2009,27(13):2269-2277.

[5]KOONG AC,LE QT,HO A,et al.PhaseⅠstudy of stereotatic radiosurgery in patients with locally advanced pancreatic cancer[J].Int J Radiat Oncol Biol Phys,2004,58(4):1017-1021.

[6]LING ZH,SUN QQ,ZHANG YW,et al.Effect of gemcitabine in enhancing the radiosensitivity of Hep G2 hepatoma cells and the possible mechanism[J].J South Med Univ,2011,31(12):1993-1996.(in Chinese)凌志海,孙权权,张耀伟,等.吉西他滨增强肝癌Hep G2细胞体外辐射敏感性的机制研究[J].南方医科大学学报,2011,31(12):1993-1996.

[7]BTTGER TC,JUNGINGER T.Factors influencing morbidity and mortality after pancreatic duodenectomy:critical analysis of 221 resections[J].World J Surg,1999,23(2):164-171.

[8]ZHENG W,NIE Q,KANG JB,et al.Clinical observation of stereotactic radiotherapy combined with gemcitabine for pancreatic carcinoma[J].Chin Clin Oncol,2011,16(11):995-1000.(in Chinese)郑伟,聂青,康静波,等.立体定向放疗联合吉西他滨治疗胰腺癌的临床观察[J].临床肿瘤学杂志,2011,16(11):995-1000.

[9]PAN DJ,WANG B,ZHOU XJ,et al.Clinical study on gemcitabine combined with gamma rays stereotactic body radiation therapy for patients with locally advanced pancreatic cancer[J].J Mod Oncol,2015,23(3):363-366.(in Chinese)潘德键,王标,周锡建,等.盐酸吉西他滨联合伽玛射线立体定向体部放疗治疗局部晚期胰腺癌的临床研究[J].现代肿瘤医学,2015,23(3):363-366.

[10]BTTGER TC,JUNGINGER T.Treatment of tumours of the pancreatic head with suspected but unproved malignancy:is a nihilistic approach justified?[J].World J Surg,1999,23(2):158-162.

[11]REN G,WANG J,XIA TY,et al.Interpretation of document in Chinese expert consensus on comprehensive diagnosis and treatment of pancreatic cancer(2014 Edition)[J].J Clin Hepatol,2014,30(12):1249-1251.(in Chinese)任刚,王竞,夏廷毅.《胰腺癌综合诊治中国专家共识(2014年版)》放射治疗部分的解读[J].临床肝胆病杂志,2014,30(12):1249-1251.

[12]LOEHRER PJ Sr,FENG Y,CARDENES H,et al.Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer:an Eastern Cooperative Oncology Group trial[J].J Clin Oncol,2011,29(31):4105-4112.

[13]MUKHERJEE S,HURT CN,BRIDGEWATER J,et al.Gemcitabine-based or capecitabine chemoradiotherapy for locally advanced pancreatic cancer(SCALOP):a multicentre,randomized,phaseⅡtrial[J].Lancet Oncol,2013,14(4):317-326.

[14] MOORE MJ,GOLDSTEIN D,HAMM J,et al.Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer:a phaseⅢtrial of the National Cancer Institute of Canada Clinical Trials Group[J].J Clin Oncol,2007,25(15):1960-1966.

施引文献

资源附件(0)

访问统计